MSN: Brent and Harrow stations among five new ones to be prioritised for step-free access
Brent and Harrow stations among five new ones to be prioritised for step-free access
Harrow believes the planned Phase 3 trial represents an important opportunity to further strengthen the clinical and commercial profile of TRIESENCE. The study is designed to generate robust data supporting its use in managing post-operative inflammation and pain following cataract surgery, with the potential to expand the product’s label.
Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE ...
A visually and hearing impaired woman from Brent says it’s “vitally important” access is improved across the Tube network after two local stations were added to a list for potential improvements. Two ...
The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.
NASHVILLE, Tenn. -- (BUSINESS WIRE)---- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended . The Company also posted its first quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com.
NASHVILLE, Tenn. -- (BUSINESS WIRE)--Jan. 27, 2025-- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced the launch of its “Harrow Cares” program through a strategic partnership with Cencora (NYSE: COR). Harrow Cares delivers a comprehensive suite of high‑quality access and affordability services, enhancing support for retina specialists, their ...
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease